Answer
Breastfeeding should be discontinued during mosunetuzumab (Lunsumio) treatment because a risk to newborns or infants cannot be excluded.
Sources for this answer
- Lunsumio 1 mg and 30 mg concentrate for solution for infusionRoche Products Limited · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 10Document updated
Sources checked